Answers are grounded in this paper and cite their sources.
, it elicits robust cellular, humoral, and mucosal immune responses against SARS-CoV-2 and its major variants in both respiratory and systemic compartments, with evidence of tissue-resident memory responses. Following intranasal administration, the antigen conferred complete cross-protection against lethal challenge with representative SARS-CoV-2 and its variants. Notably, a low antigen dose of 0.2 μg in a two-dose regimen achieved full protection. Immunomics further revealed that this design induces a broader T and B cell repertoire. Collectively, this study establishes a generalizable framework that combines epitope-optimized antigen design with FcRn-mediated mucosal delivery, providing a promising strategy for broad-spectrum vaccine development against rapidly evolving respiratory viruses.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: